These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 25899302

  • 1. A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience.
    Sheerin NS, Kavanagh D, Goodship TH, Johnson S.
    QJM; 2016 Jan; 109(1):27-33. PubMed ID: 25899302
    [Abstract] [Full Text] [Related]

  • 2. Practical issues in using eculizumab for children with atypical haemolytic uraemic syndrome in the acute phase: A review of four patients.
    Terano C, Ishikura K, Hamada R, Yoshida Y, Kubota W, Okuda Y, Shinozuka S, Harada R, Iyoda S, Fujimura Y, Hamasaki Y, Hataya H, Honda M.
    Nephrology (Carlton); 2018 Jun; 23(6):539-545. PubMed ID: 28387984
    [Abstract] [Full Text] [Related]

  • 3. Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort.
    Mallett A, Hughes P, Szer J, Tuckfield A, Van Eps C, Cambell SB, Hawley C, Burke J, Kausman J, Hewitt I, Parnham A, Ford S, Isbel N.
    Intern Med J; 2015 Oct; 45(10):1054-65. PubMed ID: 26247170
    [Abstract] [Full Text] [Related]

  • 4. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
    Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, van de Kar NC, Vande Walle J, Ogawa M, Bedrosian CL, Licht C.
    Kidney Int; 2016 Mar; 89(3):701-11. PubMed ID: 26880462
    [Abstract] [Full Text] [Related]

  • 5. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.
    Fakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO, Menne J, Minetti EE, Provôt F, Rondeau E, Ruggenenti P, Weekers LE, Ogawa M, Bedrosian CL, Legendre CM.
    Am J Kidney Dis; 2016 Jul; 68(1):84-93. PubMed ID: 27012908
    [Abstract] [Full Text] [Related]

  • 6. Prevention and treatment of atypical haemolytic uremic syndrome after kidney transplantation.
    Okumi M, Tanabe K.
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():9-13. PubMed ID: 26988663
    [Abstract] [Full Text] [Related]

  • 7. Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooled post hoc analysis.
    Legendre CM, Campistol JM, Feldkamp T, Remuzzi G, Kincaid JF, Lommelé Å, Wang J, Weekers LE, Sheerin NS.
    Transpl Int; 2017 Dec; 30(12):1275-1283. PubMed ID: 28801959
    [Abstract] [Full Text] [Related]

  • 8. Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis.
    Socié G, Caby-Tosi MP, Marantz JL, Cole A, Bedrosian CL, Gasteyger C, Mujeebuddin A, Hillmen P, Vande Walle J, Haller H.
    Br J Haematol; 2019 Apr; 185(2):297-310. PubMed ID: 30768680
    [Abstract] [Full Text] [Related]

  • 9. Life-threatening pregnancy-associated atypical haemolytic uraemic syndrome and its response to eculizumab.
    Gately R, San A, Kurtkoti J, Parnham A.
    Nephrology (Carlton); 2017 Feb; 22 Suppl 1():32-35. PubMed ID: 28176475
    [Abstract] [Full Text] [Related]

  • 10. Failure of first meningococcal vaccination in patients with atypical haemolytic uraemic syndrome treated with eculizumab.
    Gäckler A, Kaulfuß M, Rohn H, Vogel U, Claus H, Feldkamp T, Kribben A, Witzke O.
    Nephrol Dial Transplant; 2020 Feb 01; 35(2):298-303. PubMed ID: 29992261
    [Abstract] [Full Text] [Related]

  • 11. Suspected atypical haemolytic uraemic syndrome in two post-partum patients with foetal-death in utero responding to eculizumab.
    Chua J, Paizis K, He SZ, Mount P.
    Nephrology (Carlton); 2017 Feb 01; 22 Suppl 1():18-22. PubMed ID: 28176472
    [Abstract] [Full Text] [Related]

  • 12. Absence of thrombocytopaenia and/or microangiopathic haemolytic anaemia does not reliably exclude recurrence of atypical haemolytic uraemic syndrome after kidney transplantation.
    Krishnan AR, Siva B, Chakera A, Wong G, Wong D, Lim WH.
    Nephrology (Carlton); 2017 Feb 01; 22 Suppl 1():28-31. PubMed ID: 28176477
    [Abstract] [Full Text] [Related]

  • 13. Economic Impact of Early-in-Hospital Diagnosis and Initiation of Eculizumab in Atypical Haemolytic Uraemic Syndrome.
    Ryan M, Donato BMK, Irish W, Gasteyger C, L'Italien G, Laurence J.
    Pharmacoeconomics; 2020 Mar 01; 38(3):307-313. PubMed ID: 31828738
    [Abstract] [Full Text] [Related]

  • 14. Irreversible severe kidney injury and anuria in a 3-month-old girl with atypical haemolytic uraemic syndrome under administration of eculizumab.
    Okuda Y, Ishikura K, Terano C, Harada R, Hamada R, Hataya H, Ogata K, Honda M.
    Nephrology (Carlton); 2016 Mar 01; 21(3):261-5. PubMed ID: 26818219
    [Abstract] [Full Text] [Related]

  • 15. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases.
    Fakhouri F, Delmas Y, Provot F, Barbet C, Karras A, Makdassi R, Courivaud C, Rifard K, Servais A, Allard C, Besson V, Cousin M, Châtelet V, Goujon JM, Coindre JP, Laurent G, Loirat C, Frémeaux-Bacchi V.
    Am J Kidney Dis; 2014 Jan 01; 63(1):40-8. PubMed ID: 24021908
    [Abstract] [Full Text] [Related]

  • 16. Eculizumab in paediatric atypical haemolytic uraemic syndrome: Lessons learned from a single-centre experience in the United Arab Emirates.
    Kumar G, Al-Masri O, Alismaili Z, Tawfik E, Al-Ghabra MK, Ilyas SH, Al-Khasawneh E.
    J Paediatr Child Health; 2019 Oct 01; 55(10):1237-1240. PubMed ID: 30714243
    [Abstract] [Full Text] [Related]

  • 17. Long-term remission with eculizumab in atypical haemolytic uraemic syndrome.
    Carter S, Hewitt I, Kausman J.
    Nephrology (Carlton); 2017 Feb 01; 22 Suppl 1():7-10. PubMed ID: 28176479
    [Abstract] [Full Text] [Related]

  • 18. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases.
    Ardissino G, Testa S, Possenti I, Tel F, Paglialonga F, Salardi S, Tedeschi S, Belingheri M, Cugno M.
    Am J Kidney Dis; 2014 Oct 01; 64(4):633-7. PubMed ID: 24656451
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of eculizumab treatment after kidney transplantation in patients with atypical haemolytic uraemic syndrome.
    van den Brand JA, Verhave JC, Adang EM, Wetzels JF.
    Nephrol Dial Transplant; 2017 Jan 01; 32(suppl_1):i115-i122. PubMed ID: 28391343
    [Abstract] [Full Text] [Related]

  • 20. Success of eculizumab in the treatment of atypical hemolytic uremic syndrome.
    Baskin E, Gulleroglu K, Kantar A, Bayrakci U, Ozkaya O.
    Pediatr Nephrol; 2015 May 01; 30(5):783-9. PubMed ID: 25384530
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.